ClinicalTrials.gg
CompletedNCT00288197Updated Jun 12, 2008

A Study To Assess The Efficacy And Safety Of Voriconazole In Chinese Patients With Serious Deep Tissue Fungal Infections

A Phase 4 interventional study of voriconazole in Invasive Fungal Infections, sponsored by Pfizer. Completed at 10 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-06-12.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
77
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Invasive Fungal Infections with a site in China — 12 open to participants now, 12 under way, none of them phase 3. Invasive Fungal Infections · China.

Enrollment
6th of 12
77 · median 74
Started
2006
the only one that year
Phase 4
5 of 29
1 open now
Registered
1st of 29
by date
Lead sponsor
2 of 29
Pfizer

Among the 29 studies in Invasive Fungal Infections with a site in China, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2006, is one of 5 in phase 4, and was the 1st registered.

Invasive Fungal Infections

136 studies on the registry are indexed under Invasive Fungal Infections; 33 are open to participants now.

Browse Invasive Fungal Infections studies →

Open to participants now

12 of the 29 studies in Invasive Fungal Infections with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Invasive Fungal Infections studies recruiting now, 12 (60%) set no upper age limit and 5 (25%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Invasive Fungal Infections with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of voriconazole in Chinese patients with proven or probable deep tissue fungal infections.

03

Conditions studied

  • Invasive Fungal Infections
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with proven or probable invasive fungal infections including subjects who have failed to respond to, or have an intolerance to other approved antifungal treatments and with approval for salvage treatment by Principal Investigator and Pfizer.

Exclusion criteria

Exclusion Criteria:

  • Subjects who are showing continuing improvement with other antifungal agents, including amphotericin B, itraconazole, nystatin, fluconazole, flucytosine and miconazole.
  • Subjects with an invasive fungal infection caused by a fungus (such as Mucor) that is not in the antifungal spectrum of voriconazole.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
77 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Percent of subjects with a Global Efficacy assessment of either "cured" or "improved" by Week 6 visit.

Secondary outcomes

  1. Safety assessment during the study period (Adverse events observed between start of treatment and follow-up visit).

  2. Percent of subjects with a Global Efficacy assessment of either "cured" or "improved" at the time when IV administration is completed

07

Study locations

10 sites
  • Pfizer Investigational Site
    Guangzhou, Guangdong 510080, China
  • Pfizer Investigational Site
    Wuhan, Hubei 430022, China
  • Pfizer Investigational Site
    Wuhan, Hubei 430030, China
  • Pfizer Investigational Site
    Beijing, 100083, China
  • Pfizer Investigational Site
    Beijing, 100853, China
  • Pfizer Investigational Site
    Hangzhou, 310003, China
  • Pfizer Investigational Site
    Shanghai, 200040, China
  • Pfizer Investigational Site
    Shanghai, 200080, China
  • Pfizer Investigational Site
    Tianjin, 300020, China
  • Pfizer Investigational Site
    Tianjin, 300052, China
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2006
First posted
Feb 7, 2006
Start
Jan 2006
Primary completionActual
Jun 2007
CompletionActual
Jun 2007
Last update
Jun 12, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00288197
Lead sponsor
Pfizer
First posted
Feb 7, 2006
Start date
Jan 2006
Primary completion
Jun 2007
Completion
Jun 2007
Last update
Jun 12, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion